CIMIVIR- L Biocon’s shares after the announcement of the start of the day’s high of Rs 510.5 risen as much as 6 percent Hakjav technology a new therapy for the treatment of major hepatitis-C.
CIMIVIR- Ledipasvir 90 mg and Sofosbuvir 400 mg of L is a fixed dose. India under license from Gilead’s drug regulator, global head being manufactured in India which Ledipasvir- Sofosbuvir combination.
Biocon in India at a fraction of the global cost CIMIVIR- L provided to patients.
CMD of Biocon, the hepatitis C drug Gilead is one of several licensees. And about a year ago that we launched another drug medication then the next generation.
Ms. Shaw moment for the new drug is close to Rs 200 crore in the Indian market, it is expected to rise to Rs 500 crore.
90 licensees in other developing countries may be eligible for the drug market, the market size is expected to increase to Rs 1,000 crore.
10:12, Biocon shares a flat broader market outperforming, were up 5.4 per cent at 507.